Follow-on biologics
Subtitle: hearing of the Committee on Health, Education, Labor, and Pensions, United States Senate, One Hundred Tenth Congress, first session, on examining Food and Drug Administration follow-on biologics, generally referred to as a biotechnology-derived protein drug (or biologic) that is comparable to a novel, previously approved biologic and that is approved with less supporting data than the innovator biologic, March 8, 2007.
Series: S. hrg -- 110-375
Publisher: U.S. G.P.O.; For sale by the Supt. of Docs., U.S. G.P.O.
Published: 2008
Place of publication: Washington
Language: eng
Number of pages: 78
ISBN-13: 9780160817557
Subjects: Pharmaceutical biotechnology -- Government policy -- United States.; Pharmaceutical biotechnology -- United States -- Patents.; Pharmaceutical technology -- Government policy -- United States.; Drug development -- Government policy -- United States.
Genres: Patents.
Notes: Shipping list no.: 2009-0050-P.

Includes bibliographical references.